News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Docs Reveal CDER Chief Skirted Procedures Approving Sarepta (SRPT)'s Controversial Drug Eteplirsen



8/3/2017 8:21:17 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
While FDA commissioner Rob Califf was trying to navigate an internal civil war at the agency over its controversial decision to provide an accelerated approval for Sarepta’s eteplirsen, John Jenkins, then head of the Office of New Drugs, sent him a memo which detailed a blistering attack on CDER chief Janet Woodcock.

It was Woodcock who demanded, and won, the argument in favor of an accelerated OK of the Duchenne muscular dystrophy drug.

Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES